Physician profile
Hannah Y Wen
NPI 1760688816
$60,284.12
in general payments reported to CMS, 2019-2025
5 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.33 · 2020: $1,125 · 2021: $10K · 2022: $15K · 2023: $3,253 · 2024: $15K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $166 · Travel and Lodging: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,148.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,402.50 |
| Food and Beverage | $165.54 |
| Travel and Lodging | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $43,464.74 | 2021-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $9,450.00 | 2020-2024 | |
| Daiichi Sankyo INC. | $4,960.00 | 2025 | Enhertu |
| Roche Diagnostics Corporation | $2,352.05 | 2023 | Pathway Anti-Her-2/Neu (4b5) Rabbit Monoclonal Primary Antibody |
| Genentech USA, INC. | $57.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Wen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.